Biopharma | April 14, 2026
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Subscribe To Our Newsletter & Stay Updated
